GERRESHEIMER de plusieurs mois. Il a été conçu pour être utilisé à domicile, ce qui évite au patient de devoir se rendre chez un professionnel de santé pour l’admi- nistration d’un médicament, allégeant ainsi la charge qui pèse sur le secteur des soins de santé et offrant une plus grande indépendance au patient. La diminution des déplacements des patients entraîne également une réduc- tion de l’empreinte carbone. En adoptant les principes de l’éco-conception, les développeurs ont cherché à augmenter la durée de vie de ce dispositif et à réduire les déchets en le rendant partiellement réutilisable, tout en maintenant les normes d’hy- Figure 2 : Études sur les préférences des patients Réponse de 40 patients concernant l’utilisation giène essentielles. Enfin, l’impact de d’un injecteur corporel (%) la conservation frigorifique nécessaire Figure 3: Patient preference study Response of 40 patients to the idea of using an on-body injector (%)des produits biopharmaceutiques a été pris en compte, ainsi que la manière long and stressful intravenous infu- patients in Europe and the US. The By 2025, refractory hypercholestero- sions in a hospital setting to treat their results showed that 68% preferred lemia will be the predominant indi- condition. Homecare enables patients the idea of using an on-body injector cation in approximately 4.3 million to return home as quickly as possible versus standard subcutaneous injec- people.4 Treatment with the fully – for example, after a hospital stay – tion and over 70% were in favour of humanised monoclonal antibody evi- even if they still require certain therapy self-administration at home (Figure 3).3 nacumab has been shown to inhibit and care measures due to their illness. In terms of impact on CO2 footprint, lipoprotein lipase and endothelial Other therapies may not need to be using the example of a 28-year-old lipase and would be applied subcu- administered in a hospital or other care Swiss patient suffering from familial taneously once a month for a period facility at all, but could be self-adminis- hypercholesterolemia since childhood, of approximately tered subcutaneously at home after a calculations can be made to determine 17 months.5,6 single visit to the doctor. an approximate decrease in carbon Subcutaneous self-administration has footprint due to at-home therapy admi- The average person living in Swit- been shown to improve patient quality nistration. With hypercholesterolemia, zerland generates 14 tons of CO2 of life and reduce treatment time. To there is too much cholesterol in the per year, according to the myclimate evaluate patient preference, Gerreshei- blood, which can cause deposits in web page. By not travelling to hos- mer conducted a small-scale patient the vessels and lead to atherosclero- pital by car for treatment once per preference study of 40 breast cancer sis-related cardiovascular disease. month for the 17-month treatment 22 The Pharmaceutical Post 20 / Octobre - 2024